UP!
| 2016-06-09 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-06-09 | Reiterated Rating | Brean Capital | Buy | $16.00 |
| 2016-06-09 | Reiterated Rating | Needham & Company LLC | Buy | $16.00 |
| 2016-05-10 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-05-10 | Reiterated Rating | Needham & Company LLC | Buy | |
| 2016-05-09 | Reiterated Rating | Brean Capital | Buy | |
| 2016-04-18 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-03-28 | Initiated Coverage | Brean Capital | Buy | $16.00 |
| 2016-03-09 | Reiterated Rating | Canaccord Genuity | Buy | $16.00 |
| 2016-03-08 | Reiterated Rating | Needham & Company LLC | Buy | $16.00 |
| 2016-01-04 | Initiated Coverage | WBB Securities | Buy | $8.00 |
| 2015-12-29 | Initiated Coverage | WBB Securities | Buy | $8.00 |
| 2015-11-17 | Reiterated Rating | Needham & Company LLC | Buy | $16.00 |
| 2015-11-17 | Reiterated Rating | Canaccord Genuity | Buy | $16.00 |
| 2015-11-16 | Lower Price Target | RBC Capital | Outperform | $18.00 to $17.00 |
| 2015-11-16 | Lower Price Target | Royal Bank Of Canada | Outperform | $18.00 to $17.00 |
| 2015-08-20 | Reiterated Rating | Needham & Company LLC | Buy | $16.00 |
| 2015-06-10 | Initiated Coverage | Needham & Company LLC | Buy | $16.00 to $16.00 |
| 2015-04-02 | Reiterated Rating | Canaccord Genuity | Buy | $16.00 |
| 2015-02-12 | Set Price Target | Canaccord Genuity | Buy | $16.00 |
| 2014-06-02 | Initiated Coverage | JMP Securities | Outperform | $15.00 |
| 2014-05-29 | Initiated Coverage | Canaccord Genuity | Buy | $18.00 |
| 2014-05-29 | Initiated Coverage | RBC Capital | Outperform | $17.00 |
| 2016-06-09 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-06-09 | Reiterated Rating | Brean Capital | Buy | $16.00 |
| 2016-06-09 | Reiterated Rating | Needham & Company LLC | Buy | $16.00 |
| 2016-05-10 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-05-10 | Reiterated Rating | Needham & Company LLC | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In SCYX 36 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| FEDERATED INVESTORS INC /PA/ | 5.17M |
| Broadfin Capital, LLC | 2.00M |
| CAXTON CORP | 1.72M |
| Vanguard Group, Inc | 1.32M |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1.30M |
| UBS OCONNOR LLC | 0.54M |
| BlackRock Inc. | 0.42M |
| Iguana Healthcare Management, LLC | 0.40M |
| DAFNA Capital Management LLC | 0.40M |
| GEODE CAPITAL MANAGEMENT, LLC | 0.28M |
| DAVIDSON D A & CO | 0.21M |
| BRIDGEWAY CAPITAL MANAGEMENT INC | 0.15M |
| KCG Holdings, Inc. | 0.11M |
| STATE STREET CORP | 78630 |
| BlackRock Fund Advisors | 70370 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Ventech Capital II | 4.87% (414211) | SCYX / |
| Taglietti Marco | 4.75% (404000) | DCTH / FRX / NRX / SCYX / |
| FCPR Biotechnology Fund | 3.47% (295077) | SCYX / |
| Nothias Jean-Yves | 3.47% (295077) | SCYX / |
| F.C.P.R. Genavent | 2.79% (237598) | SCYX / |
| Angulo Gonzalez David Chief Medical Officer | 1.20% (101790) | SCYX / |
| ALTA BIOPHARMA PARTNERS II LP | 0.54% (45736) | SCYX / |
| Macdonald Guy | 0.47% (40000) | SCYX / TTPH / |
| HASTINGS DAVID C | 0.37% (31834) | INCY / SCYX / UNIS / |
| KIRBY PAMELA J | 0.30% (25590) | SCYX / |
| Francois Eric Chief Financial Officer | 0.29% (24917) | SCYX / |
| Machado Clarence Patrick | 0.24% (20000) | AAVL / CMRX / ECYT / MDVN / SCYX / TKMR / |
| Langlois Patrick | 0.12% (10503) | SCYX / |
| Arthaud Laurent | 0.05% (4507) | SCYX / |
| HANHAM ANN | 0.05% (4225) | ECYT / SCYX / |
| Sukenick Scott General Counsel | 0.03% (2959) | SCYX / |
| Ribeill Yves J President and CEO | 0.01% (1190) | SCYX / |
UM